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ABSTRACT
The purpose of this study was to compare treatment satisfaction with triple nucleoside reverse
transcriptase inhibitor (NRTI) highly active antiretroviral treatment (HAART) regimens in-
cluding abacavir (ABC) to HAART regimens that include protease inhibitors (PIs) and to es-
timate the relationship between patient satisfaction and adherence to HAART. Three open-la-
bel clinical trials comparing ABC-including HAART regimens with PI-including HAART
regimens were completed, two with patients previously untreated with antiretroviral therapy
and one with patients successfully treated with PI-including HAART regimens. The HIV Treat-
ment Satisfaction Questionnaire (HIVTSQ) was completed at several time points during each
trial. Levels of patient satisfaction with the ABC and PI regimens were compared for all three
trials. The correlation between adherence and patient satisfaction scores was measured using
data from an adherence questionnaire in one of the studies. In all three clinical trials, patient
satisfaction scores were significantly higher with an ABC-including triple NRTI HAART reg-
imen than with a PI-including HAART regimen. The difference was apparent by week 4 of
the trial and was maintained throughout the trial time period. Inspection of the item responses
in the patient satisfaction questionnaire indicated that treatment convenience, flexibility, im-
pact on lifestyle, and side effects were key factors in the difference in satisfaction between the
treatment groups. In addition, patient satisfaction was shown to be significantly correlated
with adherence defined as taking 95% or more of prescribed doses. Greater satisfaction was
reported by patients given an ABC-including HAART regimen than those given a PI-includ-
ing HAART regimen. Patient satisfaction may be an indicator for better treatment adherence.
9
INTRODUCTION
SINCE THE INTRODUCTION OF highly activeantiretroviral therapy (HAART), life ex-
pectancy after diagnosis with human immun-
odeficincy virus (HIV) infection has increased
from 10–12 years to 17 years or more.1 How-
ever, HAART regimens, especially those that
include protease inhibitors (PIs), require the in-
take of many pills at specific time intervals with
different requirements for food and liquid in-
take.2 In addition, HAART regimens are asso-
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ciated with serious side effects including dys-
lipidemia and lipodystrophy.2
Several factors have been correlated with ad-
herence to HAART regimens, including pa-
tient, illness, and treatment attributes. Patient
attributes include age, mental state, and patient
belief or trust in the medication and medical
care.3,4 Illness attributes include whether or not
the HIV infection is symptomatic and the sever-
ity of those symptoms. Treatment attributes in-
clude both perceived and actual efficacy of the
treatment, quality of the physician/patient re-
lationship, pill burden, side effects, and dietary
restrictions.
Several studies have shown a negative corre-
lation between regimen complexity or pill bur-
den and adherence.5–10 Increased adherence has
also been associated with better quality physi-
cian/patient relationships.11 Patient satisfaction
with a HAART regimen is one measure of pa-
tients’ views of these treatment attributes.
Patient satisfaction can be measured with a
single general question about overall satisfac-
tion or using a multi-item measure, including
satisfaction with aspects of treatment known to
be relevant for HIV treatment regimens.12 Mea-
surement of satisfaction using a multi-item
measure rather than a single score indicates
more specifically where problems lie and
where solutions are needed.13
The primary objective of this paper is to pres-
ent patient satisfaction measures reported dur-
ing three clinical trials comparing the use of
abacavir (ABC), a nucleoside reverse tran-
scriptase inhibitor (NRTI), with the use of PIs
as part of a HAART regimen. One clinical trial
randomized patients who had responded to a
PI-including HAART regimen, predominantly
indinavir (IDV) or nelfinavir (NFV), either to
continue the PI-including regimen or to switch
the PI to ABC. The other two clinical trials com-
pared ABC-including HAART regimens to IDV
or NFV including HAART regimens for previ-
ously untreated patients. Patient satisfaction
was measured using a validated measure, the
nine-item HIV Treatment Satisfaction Ques-
tionnaire (HIVTSQ).12
The secondary objective of this paper is to
present the results of an analysis of the corre-
lation between adherence and patient satisfac-
tion using data from one international study of
previously untreated patients.
MATERIALS AND METHODS
Data on patient satisfaction and adherence
with different HAART regimens were collected
over 48 weeks in three clinical trials, each com-
paring a combination of three NRTIs with a
combination of a PI and two NRTIs. These tri-
als were all randomized open-label studies con-
ducted at multiple sites for patients who were
either successfully treated with their first anti-
retroviral therapy (ART) regimen or previously
untreated with ART. The primary and sec-
ondary clinical endpoints included the propor-
tion of study participants with viral load less
than 400 copies per milliliter at 48 weeks and
the change in CD4 cell count from baseline to
48 weeks. The designs of these studies are il-
lustrated in Figure 1 and summarized below.
• In trial CNA30017, virologically suppressed
patients from 29 sites in Europe and Canada
(n  211) were randomized to continue their
current two NRTIs plus PI regimen or to
switch from the PI to ABC. Patient satisfac-
tion was measured at study weeks 4, 8, 12,
16, 24, 32, 40, and 48.
• In trial CNA3014, previously untreated pa-
tients from 19 sites in Argentina, Brazil, Mex-
ico, Italy, and Thailand (n  329) were ran-
domized to receive zidovudine/lamivudine
combined (ZDV 300 mg/3TC 150 mg) (Com-
bivir®, GlaxoSmithKline Research Triangle
Park, NC) twice per day plus ABC 300 mg
twice per day or ZDV/3TC plus IDV 800 mg
three times per day. Approximately 25% of
patients had an initial viral load of more than
100,000 copies per milliliter. Patient satisfac-
tion and adherence were measured at study
weeks 4, 8, 12, 16, 24, 36, and 48.
• In trial CNAF3007, previously untreated pa-
tients from 61 sites in France (n  195) were
randomized to receive ZDV 300 mg/3TC 150
mg twice per day plus ABC 300 mg twice per
day or ZDV/3TC plus NFV 750 mg three
times per day. Approximately 6% of patients
had an initial viral load of more than 100,000
copies per milliliter. Patient satisfaction was
measured at study weeks 4, 8, 12, 16, 24, 36
and 48.
Regimen-dosing requirements (number of
pills, dosing regimen, and dosing conditions
JORDAN ET AL.10
such as timing and amounts of food and water
consumption) for the two studies of previously
untreated patients, CNA3014 and CNAF3007,
are shown in Table 1. The dosing requirements
for the third study, CNA30017, are not pre-
sented in Table 1 because the study included a
wide variety of NRTIs and PIs with a variety
of regimen-dosing requirements, although the
majority of the patients in the trial received
ZDV and 3TC and IDV or NFV.
In all three clinical trials, participants com-
pleted the nine-item HIVTSQ. This measure
has been shown to be valid, reliable, and sen-
sitive to differences between treatment groups
in a study comparing satisfaction with two
PIs.12 The nine aspects of satisfaction included
in the measure are shown in Table 2. Likert-
scale response options for each item range from
0 to 6, with zero indicating the least favorable
option (e.g., very dissatisfied) and 6 the most
favorable (e.g., very satisfied). Principal com-
ponents analyses suggested that patients’ rat-
ings of the nine items could be summed to com-
pute a total satisfaction score. This sum was
then converted from a 0–54 range to a 0–100
range for presentation of the results.
The HIVTSQ was originally validated in En-
glish for the United States and Canada by the
questionnaire developers.12 The questionnaire
was then translated by a translation agency
(without the knowledge or involvement of the
developers) into English for the United King-
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FIG. 1. Trial design. *Nucleoside reverse transcriptase
inhibitor (NRTI) combinations used most frequently in
the clinical trial were ZDV/3TC, either combined in a sin-
gle pill or as separate components, and d4T/3TC. Of the
167 patients in whom NRTI identity was known (16 pa-
tients had missing values) ZDV/3TC combined  63
(37.5%), ZDV/3TC separately  50 (30%), 3TC/d4T  41
(24.4%), ddI/d4T  9 (5.4%), ZDV/ddI  3 (1.8%),
ZDV/ddC  1 (0.6%). ** NFV and IDV comprised the ma-
jority of PI use, while RTV and SQV were used to a lesser
extent. Of the 80 patients in whom PI identity was known
(11 patients had missing values) IDV  39 (48.8%),
NFV  18 (22.5%), SQV  7 (8.8%), SQV/RTV  12
(15%), RTV  4 (5%). 3TC, lamivudine; ABC, abacavir;
d4T, stavudine; ddC, zalcitabine, ddI, didanosine; IDV,
indinavir; NFV, nelfinavir; RTV, ritonavir; SQV,
saquinavir; ZDV, zidovudine; ZDV/3TC combined,
Combivir®, PI, protease inhibitor.
TABLE 1. REGIMEN COMPARISON FROM CNA3014 AND CNAF3007
# Separate # Pills Dosing Food/Fluid
Regimen Application study meds per day frequency requirements
ZDV 300 mg and 2  2  4 BID/BID None
3TC 150 mg
combined/
ABC 300 mg CNA3014,CNAF3007 2
ZDV 300 mg and 2  9  11 BID/TID With food
3TC 150 mg 
combined/
NFV 750 mg CNAF3007 2
ZDV 300 mg and CNA3014 2 2  6  8 BID/TID Empty stomach,
3TC 150 mg with water
combined/ 1.5qt/d
IDV 800 mg
ZDV, zidovudine; 3TC, lamivudine; ABC, abacavir; NFV, nelfinavir; IDV, indinavir; BID, twice per day; TID, three
times per day.
dom, French (for France, Belgium, and
Canada), Spanish (for Argentina and Mexico),
Italian, Portuguese (for Brazil), and Thai, to be
used in the multinational clinical trials. Once
the clinical trials were completed, a separate
psychometric and linguistic validation was
conducted by the developers for each ques-
tionnaire translation. Three translations—Ital-
ian, Portuguese for Brazil, and French for
Canada—were found to be inadequate based on
psychometric validation techniques, including
principal components analysis of factor loadings
and Cronbach  coefficients of internal consis-
tency reliability. The data from these three trans-
lations were excluded from the analyses pre-
sented in this paper. For the translations retained
in the analysis (English for the United Kingdom;
French for France and Belgium, Spanish for Ar-
gentina and Mexico, and Thai), statistical vali-
dation supported computation of the nine-item
total satisfaction scale. In each language, the prin-
cipal components analysis factor loadings for the
nine HIVTSQ items all exceeded 0.4. Cronbach
 coefficient of internal consistency and reliabil-
ity ranged from 0.85 (English for the United
Kingdom) to 0.90 (Spanish for Argentina).
Medication adherence data in trial CNA3014
were obtained by completion of a seven-item
adherence questionnaire by the study partici-
pants.10 The questionnaire included two ques-
tions about the number of missed doses per week
and the number of delayed doses (longer than 2
hours) per week over the past 4 weeks, as well
as questions about the longest period of consec-
utive missed doses, difficulty in taking the drugs,
and reasons for nonadherence. The study par-
ticipant’s adherence measure used in this study,
95% or more adherence or less than 95% adher-
ence to prescribed doses, was determined from
his or her response to the question, “On average
over the past 4 weeks, please estimate how of-
ten per week you have missed taking doses of
your anti-HIV medicines.” Response options
ranged from, “I have not missed a dose in the
last 4 weeks” and “I have missed less than one
dose a week in the last 4 weeks,” to “I have
missed more than 7 doses a week in the last 4
weeks.” Those whose response to this question
indicated that they had missed less than one dose
per week in the last 4 weeks were judged to be
95% or more adherent. The 95% adherence cut-
off was selected based on previous studies eval-
uating the minimum adherence threshold re-
quired to adequately suppress HIV.14,15
Statistical analysis
In all three studies, the mean total satisfac-
tion scores at each visit were compared across
the treatment regimens.
In the switch study (CNA30017), treatment
groups were also compared based on changes
in mean total satisfaction scores between base-
line and last time point on randomized therapy
(LTORT) by analysis of variance (ANOVA) ad-
justing for age, gender, and country.
In the two studies of previously untreated
patients (CNA3014 and CNAF3007), treatment
groups were compared based on LTORT total
satisfaction scores using ANOVA adjusting for
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TABLE 2. HIV TREATMENT SATISFACTION QUESTIONNAIRE ITEMSa
Items
How satisfied are you with your current treatment?
How well controlled do you feel your HIV has been recently?
How satisfied are you with the nature and extent of any unwanted side effects involved with your present form
of treatment?
How convenient have you been finding your treatment to be recently?
How flexible have you been finding your treatment to be recently?
How satisfied are you with your understanding of your HIV?
How satisfied are you with the extent to which the treatment fits in with your lifestyle?
Would you recommend this combination of treatment to someone else with HIV?
How satisfied would you be to continue with your present form of treatment?
aResponse options are scored on a Likert scale between 0 (least favorable option) and 6 (most favorable option)
age, gender, and country. Responses to indi-
vidual items on the treatment satisfaction ques-
tionnaire were also compared across treatment
regimens in all three studies using the propor-
tion of patients with scores of 5 or 6 on each
item to reflect a high level of satisfaction.
Multiple logistic regression analysis was
conducted with data collected in CNA3014 to
determine the relationship between self-re-
ported adherence to 95% or more of prescribed
doses and a set of explanatory variables, treat-
ment group, total satisfaction score, age, gen-
der, baseline HIV-1 RNA, and CD4 cell count.
RESULTS
The demographic and baseline disease char-
acteristics of the study participants providing
treatment satisfaction data are presented in
Table 3. With the exception of CD4 cell count
in the CNAF3007 trial, there were no differ-
ences between the treatment arms in demo-
graphic and baseline disease characteristics
within each trial. Comparing across trials, the
previously treated group in trial CNA30017
was older and had a higher CD4 cell count
than the previously untreated patients in trials
CNA3014 and CNAF3007.
The clinical results from these three trials in-
dicated that, at 48 weeks, the ABC-including
regimen had similar or better efficacy mea-
sured both in terms of viral load reduction and
CD4 cell count increase compared to the PI-
including regimens.16–18
Figure 2 presents the total satisfaction scores
from the three clinical trials over the full trial time
period. In the switch trial (CNA30017), those
who remained on PI therapy reported total sat-
isfaction scores that stayed relatively constant
over the full trial time period. Those who were
switched to ABC reported a rapid increase in sat-
isfaction, apparent when measured at week 4 af-
ter start of treatment, and this gain was main-
tained for the remaining study period. In the
trials including only previously untreated pa-
tients (CNA3014 and CNAF3007), higher satis-
faction for those on ABC-including regimens
compared to those on PI-including regimens was
observed at 4 weeks and remained relatively sta-
ble for the full 48-week trial time period.
Figure 3 presents data comparing the change
in total satisfaction scores in patients receiving
ABC and PI-including regimens between 
baseline and LTORT in the switch study
(CNA30017). These results show that, while sat-
isfaction decreased slightly for those who re-
mained on the PI-including regimens, those who
were switched to the ABC-including regimen re-
ported a significant increase in satisfaction (p 
0.001) compared to those remaining on the PI-
including regimen. Subgroup analysis of the
CNA30017 data shows a trend toward higher
patient satisfaction for those who were given
SATISFACTION WITH ABC VS. PI-HAART TREATMENT 13
TABLE 3. PATIENTS’ DEMOGRAPHIC AND DISEASE CHARACTERISTICSa
CNA30017 CNA3014 CNAF3007
ABC PI ABC IDV ABC NFV
Baseline characteristic n  89 n  86 n  121 n  122 n  86 n  84
Median age (years) 38 39 31 32 34 34
Males n (%) 78(85) 70(77) 66(55) 77(63) 60(70) 53(63)
Race n (%) N/A N/A
Asian 2(2) 0(0) 58(48) 58(48)
Black 6(7) 12(13) 0(0) 1(1)
Hispanic 5(5) 3(3) 29(24) 32(26)
Caucasian 78(85) 76(84) 32(26) 27(22)
Other 1(1) 0(0) 2(2) 4(3)
HIV-1 RNA log10 copies per milliliter
(median) N/A N/A 4.77 4.80 4.21 4.19
CD4 cell count cells/mm3
(median) 498 502 311 308 391b 439b
an’s refer to trial patients providing satisfaction data.
bp Value for difference between treatment groups 0.05.
ABC, abacavir; IDV, indinavir; NFV, nelfinavir; Pl, protease inhibitor; N/A, not available.
ZDV/3TC as a fixed-dose combination tablet
plus ABC than for other NRTI plus ABC regi-
mens [mean total satisfaction score at LTORT of
90.1 versus 84.2 (p  0.039)].
Figure 4 presents the LTORT total satisfac-
tion scores from the two trials with previously
untreated patients. In both trials, a total satis-
faction score of 86 was achieved for the ABC-
including arms. In the IDV-including arm, a to-
tal satisfaction score of 80 was achieved,
whereas in the NFV-including arm a total sat-
isfaction score of 71 was achieved at LTORT.
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FIG. 2. HIV Treatment Satisfaction Questionnaire (HIVTSQ) total satisfaction scores over time. The protease inhib-
itor (PI) group included patients taking indinavir, nelfinavir, saquinavir, ritonavir, or saquinavir/ritonavir.
The difference in patient satisfaction between
the ABC and the PI regimen was statistically
significant (p  0.001) in both trials.
A comparison of the responses to the indi-
vidual items in the patient satisfaction ques-
tionnaire for all three clinical trials is shown in
Figure 5. A greater proportion of patients were
satisfied with the ABC-including regimen than
with the PI-including regimen for each of the
scale items. In all three studies, inspection of
Figure 5 shows that the largest differences were
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FIG. 4. HIV Total Satisfaction Questionnaire (HIVTSQ) total satisfaction scores at last time point on randomized
therapy (LTORT) (CNA3014 and CNAF3007). *The protease inhibitor (PI) group included patients taking indinavir,
nelfinavir, saquinavir, or saquinavir/ritonavir.
FIG. 3. Change in total satisfaction scores from baseline
to last time point on randomized therapy (LTORT)
(CNA30017). The protease inhibitor (PI) group included
patients taking indinavir, nelfinavir, saquinavir, ritonavir,
or saquinovir/ritonavir.
seen between regimens in favor of ABC-in-
cluding regimens for treatment convenience,
flexibility, impact on lifestyle, and side effects.
Table 4 presents the results of the multiple
logistic regression analysis performed using
data from the CNA3014 study to estimate the
correlation of self-reported adherence to 95%
or more of prescribed doses with a set of ex-
planatory variables. The two explanatory vari-
ables that were significantly correlated with
high adherence are treatment group and pa-
tient satisfaction (HIVTSQ total satisfaction
score). This demonstrates an independent ef-
fect on adherence of patient satisfaction when
controlling for treatment group.
DISCUSSION
The main strength of the data presented in
this paper is the consistency of the findings. Pa-
tient satisfaction scores were higher with an
ABC-including regimen than with a PI-includ-
ing regimen. These results were seen in all three
clinical trials, which encompassed both previ-
ously treated and previously untreated pa-
tients from many different countries.
When specific answers on the patient satis-
faction questionnaire were examined across the
three clinical trials, it appeared that the differ-
ence in total patient satisfaction between the
ABC- and PI-including regimens was strongly
influenced by the magnitude of difference seen
in single-item responses for regimen conve-
nience, flexibility, and impact on lifestyle.
The regression results using the data from
CNA3014 showed that patient satisfaction was
highly correlated with self-reported adherence
to 95% or more of prescribed doses. This result
was found when controlling for other factors
that are correlated with adherence such as age,
gender, disease stage, and treatment. Thus, pa-
tient satisfaction may be a valuable predictor
of adherence.19
Several studies have shown a relationship
between adherence and disease outcomes, in-
dicating that better and more durable efficacy
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FIG. 5. Comparison of responses to specific HIV Total Satisfaction Questionnaire (HIVTSQ) Items at last time point
on randomized therapy (LTORT). *Results only for patients providing satisfaction data.
is achieved when patients are adherent to their
HAART regimen.14,20–24 However, it should be
noted that adherence measured by patient self-
report probably overestimates actual adher-
ence although the two measures are highly cor-
related.25,26
There are some limitations to the data pre-
sented. First, the translation methods used ini-
tially by the translation agency (without con-
sultation with the developers) were not
sufficiently rigorous to ensure good quality
translations and satisfactory psychometric
properties in all languages. This meant that the
satisfaction data from some of the countries in
the trial could not be included in the final anal-
ysis. The quality of the Italian, Brazilian Por-
tuguese and Canadian French translations have
now been improved in work conducted by spe-
cialists in linguistic validation of question-
naires in collaboration with the author (C.B.).
Other limitations include the fact that these
studies were not designed in a manner that per-
mits pooling of the data across studies; more de-
tailed analyses would have been possible with
pooled data. Another limitation was the statisti-
cally significant difference between baseline
CD4 cell counts in the two treatment groups in
trial CNAF3007, with a higher baseline CD4 cell
count in the NFV group, which might bias the
results from that study. Finally, these studies pri-
marily compared ABC-including regimens with
two PI-including regimens (NFV, IDV) given
three times per day. Currently, PI-including reg-
imens are more frequently given twice per day
or daily. The ability to generalize these findings
to similar regimens where NFV or IDV are given
twice per day or to other HAART regimens with
or without PIs is not known. To date, no open-
label trials have been published measuring pa-
tient satisfaction with other HAART regimens.
Clinicians and patients must make their
treatment choices based on both regimen effi-
cacy as well as the factors that contribute to pa-
tient satisfaction and adherence, including reg-
imen complexity and tolerability. While we
have presented patient satisfaction data com-
paring abacavir used in place of a protease in-
hibitor, there are other alternatives for treatment,
including non-nucleoside reverse transcriptase
inhibitors (NNRTI). Although no comparative
patient satisfaction data have been published for
NNRTIs, there are data from blinded studies
suggesting that regimens that include an NNRTI
may provide a superior virologic response com-
pared to other alternatives, including triple nu-
cleoside regimens that contain abacavir.27
It is important to recognize that all three clin-
ical trials described in this paper utilized an
open-label design that allowed patients to ex-
perience the full benefits of a more convenient
regimen. The effectiveness of a drug regimen
in real-world practice or in unblinded trials
may differ from the efficacy observed in
blinded clinical trials because of reduced ad-
herence or persistence for the less convenient
or flexible drug regimen.
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TABLE 4. MULTIVARIATE LOGISTIC REGRESSION ANALYSIS OF ADHERENCE TO 95% OR MORE OF
PRESCRIBED DOSES IN CNA3014
95%
Confidence
Predictor Odds ratio interval p Value
Total satisfaction score (per each 5-point increase) 1.14 1.04, 1.25 0.006
Treatment group (ABC vs. IDV) 3.55 2.01, 6.27 0.0001
Age 1.02 0.98, 1.06 0.304
Gender (male vs. female) 1.33 0.74, 2.41 0.339
Baseline HIV-1 RNA (per each log10 increased) 1.12 0.68, 1.83 0.666
Baseline CD4 cells 1.00 0.99, 1.00 0.225
ABC, abacavir; IDV, indinavir.
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